
The treatment is approved for adults and children, with monthly, two-weekly or weekly dosing options using a pre-filled pen.
The European Commission has authorized Novo’s FREHEMGO for routine prevention of bleeding episodes in adults and children with haemophilia A, with or without inhibitors. The drug can be given monthly, every two weeks or weekly using a single-use pre-filled pen.
The authorization follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September. Novo said approval was based on results from its FRONTIER clinical trial programme.
Novo plans to launch FREHEMGO in the first European countries in the year ahead. The treatment has also been approved in Saudi Arabia and is under review by the US Food and Drug Administration and other regulators.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.